Marc Cohen

Summary

Publications

  1. doi request reprint Improving long-term ACS management: is there a role for the new antiplatelets?
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Interv Cardiol 25:425-32. 2012
  2. doi request reprint US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    J Thromb Thrombolysis 33:230-8. 2012
  3. doi request reprint The management of patients with atrial fibrillation and dronedarone's place in therapy
    Marc Cohen
    Cardiac Cath Laboratory, Newark Beth Israel Medical Center, NJ 07112, USA
    Adv Ther 28:1059-77. 2011
  4. ncbi request reprint Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial
    Marc Cohen
    Cardiac Cath Lab Administration, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Circulation 108:III14-21. 2003
  5. ncbi request reprint The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, 07112, USA
    J Thromb Thrombolysis 19:155-61. 2005
  6. doi request reprint Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen
    Sargis Khoobiar
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, USA
    J Thromb Thrombolysis 26:85-90. 2008
  7. ncbi request reprint Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease
    Heidar Arjomand
    Division of Cardiology, Department of Medicine, MCP Hahnemann University Hospitals, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
    J Invasive Cardiol 16:271-8. 2004
  8. doi request reprint Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 55:1895-906. 2010
  9. doi request reprint Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ, USA
    Catheter Cardiovasc Interv 74:579-97. 2009
  10. doi request reprint Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial
    Marc Cohen
    Division of Cardiology, Cardiac Cath Lab, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 75:928-35. 2010

Detail Information

Publications39

  1. doi request reprint Improving long-term ACS management: is there a role for the new antiplatelets?
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Interv Cardiol 25:425-32. 2012
    ....
  2. doi request reprint US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    J Thromb Thrombolysis 33:230-8. 2012
    ....
  3. doi request reprint The management of patients with atrial fibrillation and dronedarone's place in therapy
    Marc Cohen
    Cardiac Cath Laboratory, Newark Beth Israel Medical Center, NJ 07112, USA
    Adv Ther 28:1059-77. 2011
    ....
  4. ncbi request reprint Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial
    Marc Cohen
    Cardiac Cath Lab Administration, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Circulation 108:III14-21. 2003
    ..Examination of prospectively gathered data on STEMI patients who are ineligible for reperfusion may help optimize their treatment...
  5. ncbi request reprint The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, 07112, USA
    J Thromb Thrombolysis 19:155-61. 2005
    ..We analyzed the impact of gender, and other factors, on the outcome and treatment of STEMI in the TETAMI trial and registry...
  6. doi request reprint Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen
    Sargis Khoobiar
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, USA
    J Thromb Thrombolysis 26:85-90. 2008
    ..Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known...
  7. ncbi request reprint Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease
    Heidar Arjomand
    Division of Cardiology, Department of Medicine, MCP Hahnemann University Hospitals, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
    J Invasive Cardiol 16:271-8. 2004
    ..0-2.5) in high-risk patients with atherosclerotic heart disease. Combination therapy increases the risk of minor and major bleeding, but not intracranial bleeding...
  8. doi request reprint Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 55:1895-906. 2010
    ....
  9. doi request reprint Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ, USA
    Catheter Cardiovasc Interv 74:579-97. 2009
    ....
  10. doi request reprint Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial
    Marc Cohen
    Division of Cardiology, Cardiac Cath Lab, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 75:928-35. 2010
    ..To explore clinical and bleeding outcomes in patients enrolled in the SYNERGY trial who had percutaneous coronary intervention (PCI) based on adherence to the dosing regimens of enoxaparin mandated by the protocol...
  11. ncbi request reprint A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    Marc Cohen
    HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 48:1346-54. 2006
    ....
  12. doi request reprint Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA
    Am J Cardiol 111:1727-33. 2013
    ..The use of GPIs with TRA was associated with safer outcomes than using GPIs with a nontransradial approach. This study was limited in that it was a nonrandomized retrospective analysis...
  13. pmc Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Curr Cardiol Rev 8:181-91. 2012
    ....
  14. ncbi request reprint The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 42:1348-56. 2003
    ....
  15. doi request reprint Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?
    Marc Cohen
    Division of Cardiology, Cardiology Fellowship Training Program, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Curr Opin Cardiol 24:88-94. 2009
    ....
  16. ncbi request reprint Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?
    Marc Cohen
    The Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, USA
    J Thromb Thrombolysis 26:175-82. 2008
    ..Investigators should justify components of bleeding endpoints as being clinically meaningful, sufficiently frequent in the study population, and affected by the intervention...
  17. doi request reprint Pitfalls associated with the use of current recommendations for fluoroscopy-guided common femoral artery access
    Vamsee Yaganti
    Division of Cardiology, Newark Beth Israel Medical Centre, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 81:674-9. 2013
    ..However, the use of current recommendations still results in arterial access above the inferior epigastric artery (IEA) (high stick) or below the common femoral artery (CFA) bifurcation (low stick)...
  18. ncbi request reprint The role of low-molecular-weight heparin in the management of acute coronary syndromes
    Marc Cohen
    Newark Beth Israel Medical Center, Division of Cardiology, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 41:55S-61S. 2003
    ....
  19. ncbi request reprint Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III
    Marc Cohen
    Cardiac Cath Lab, 2nd Floor Bridge, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, 07112, USA
    J Invasive Cardiol 19:525-38; quiz 539-40. 2007
    ..The addition of statins, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
  20. ncbi request reprint Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
    Circulation 115:2642-51. 2007
    ..Otamixaban, a selective and direct inhibitor of factor Xa, was investigated in patients undergoing nonurgent percutaneous coronary intervention...
  21. ncbi request reprint Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction
    Marc Cohen
    Division of Cardiology, Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA
    Am Heart Hosp J 3:82-7. 2005
    ..g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin...
  22. doi request reprint High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    Cardiovasc Drugs Ther 22:407-18. 2008
    ..Early risk stratification of patients with acute coronary syndromes (ACS), unstable angina, or non-ST-elevation myocardial infarction ensures patients receive appropriate care...
  23. doi request reprint The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Am J Emerg Med 26:932-41. 2008
    ..This review discusses each of these anticoagulant options in the context of patients transitioning to PCI...
  24. ncbi request reprint The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Cardiac Cath Lav Administration, New Jersey 07112, USA
    Am J Emerg Med 22:14-23. 2004
    ..More recent data can be interpreted as showing that regimens that are simpler and easier to administer are also clinically superior. This article reviews pharmacologic advances and evaluates the evidence for their use in EDs...
  25. pmc Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue at Osborne Terrace, Newark, NJ 07112, USA
    Cardiovasc Drugs Ther 23:489-99. 2009
    ..Non-ST-segment elevation acute coronary syndromes (NSTE ACS) are highly prevalent in the United States and globally, and are associated with significant morbidity and mortality...
  26. ncbi request reprint Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA
    Curr Med Res Opin 21:439-45. 2005
    ....
  27. doi request reprint Feasibility of the 3D RCA catheter to engage the brachiocephalic vessels during carotid angiography and stenting
    Najam Wasty
    Division of Cardiology, Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, USA
    Catheter Cardiovasc Interv 77:742-5. 2011
    ..In this study, we evaluated the feasibility of using the 3D RCA catheter which requires less manipulation in the aorta, and less training, to engage the brachiocephalic vessels...
  28. doi request reprint The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Am J Med 123:103-10. 2010
    ....
  29. pmc Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Mayo Clin Proc 84:149-60. 2009
    ..This comprehensive review contributes to the understanding of the benefit-to-risk ratio of antiplatelet therapy for patients with atherothrombosis...
  30. doi request reprint Enoxaparin: a pharmacologic and clinical review
    Zafar Iqbal
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Expert Opin Pharmacother 12:1157-70. 2011
    ..As anticoagulants play a pivotal role in the treatment of these disorders, it is vital for healthcare providers to have sufficient knowledge of their biochemical and clinical attributes...
  31. ncbi request reprint Platelets and antiplatelet therapy in patients with diabetes mellitus
    Heidar Arjomand
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    J Invasive Cardiol 15:264-9. 2003
    ..Treatment with glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention reduces mortality in diabetic patients...
  32. doi request reprint Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Cardiovasc Electrophysiol 19:885-90. 2008
    ..Because of the limited efficacy and adverse effects of current antiarrhythmics, new antiarrhythmic drugs need to be developed that provide safer and more effective rhythm control in AF...
  33. doi request reprint Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    JAMA 306:1329-37. 2011
    ..Intra-aortic balloon counterpulsation (IABC) is an adjunct to revascularization in patients with cardiogenic shock and reduces infarct size when placed prior to reperfusion in animal models...
  34. ncbi request reprint Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update
    Marc Cohen
    Division of Cardiology, MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania 19102 1192, USA
    Drugs 62:1755-70. 2002
    ..New studies will investigate the use of these agents in patients with STEMI not undergoing thrombolysis and we await the results of these studies...
  35. ncbi request reprint Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA
    Eur Heart J 24:1763-70. 2003
    ..To examine differences in patient characteristics and outcomes in 19636 patients enrolled in the USA and 3027 patients enrolled in other countries undergoing intra-aortic balloon pump (IABP) counterpulsation...
  36. ncbi request reprint Defining optimal therapy for the thrombolysis-ineligible patient
    Marc Cohen
    Division of Cardiology, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA
    Clin Cardiol 25:I23-6. 2002
    ..Blinded data for the entire patient cohort shows excellent efficacy and safety in these patients...
  37. doi request reprint Emerging antithrombotic agents: what does the intensivist need to know?
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Curr Opin Crit Care 16:419-25. 2010
    ..As thrombus consists of both fibrin and platelets, antithrombotic strategies involve anticoagulants and antiplatelets, alone or in combination...
  38. doi request reprint Interatrial thrombus-in-transit resulting in paradoxical thromboembolism
    Sargis Khoobiar
    Newark Beth Israel Medical Center, Newark, NJ, USA
    J Thromb Thrombolysis 29:127-9. 2010
    ....
  39. doi request reprint Staphylococcus capitis prosthetic valve endocarditis: report of two rare cases and review of literature
    Sandhya Nalmas
    Division of Infectious Diseases, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Heart Lung 37:380-4. 2008
    ..We report two cases of S.capitis prosthetic valve endocarditis, both involving prosthetic aortic valve and complicated by aortic root abscess. We also review the literature for this rare condition caused by this rare organism...